Table 5.
Factors associated with an adverse outcome in the course of the disease
| GOS 5 | GOS < 5 | OR (95 % CI) | P value 2015 | |
|---|---|---|---|---|
| Intracranial complications | ||||
| Cerebral ischemia | 4.3 % | 18.8 % | 5.08 (0.57–45.47) | 0.219 |
| Seizures | 8.7 % | 18.8 % | 2.423 (0.44–13.28) | 0.446 |
| Intracranial hemorrhage | 0 % | 6.3 % | 3.85a (0.178–84.19) | 0.504 |
| Intracranial venous thrombosis | 4.3 % | 9.4 % | 2.27 (0.22–23.41) | 0.632 |
| Brain edema | 8.7 % | 18.8 % | 2.42 (0.44–13.28) | 0.446 |
| Hydrocephalus | 8.7 % | 18.8 % | 2.42 (0.44–13.28) | 0.446 |
| Systemic complications | ||||
| DICa | 4.3 % | 3.1 % | 0.71 (0.04–11.98) | 1.0 |
| Sepsis | 4.3 % | 25.0 % | 7.33 (0.85–63.49) | 0.064 |
| Pneumonia | 8.7 % | 31.3 % | 4.77 (0.93–24.41) | 0.055 |
| Renal failure | 0 % | 9.4 % | 5.58b (0.27–113.50) | 0.257 |
aThese patients had thrombocytopenia, decreased antithrombin-III and clinical signs of bleeding (at sites of injections or mucous membranes). bOR was calculated adding 0.5 to each value. DIC disseminated intravasal coagulation, GOS Glasgow Outcome Scale